The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emily Jiggens, Maria Mortoglou, Guy H. Grant, Pinar Uysal-Onganer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pancreatic cancer CDK4 CDK4/6 inhibitor epidemiology Medicine R
Acceso en línea:	https://doaj.org/article/89a39525326943deba1f1cb57e8fdadd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89a39525326943deba1f1cb57e8fdadd
record_format	dspace
spelling	oai:doaj.org-article:89a39525326943deba1f1cb57e8fdadd2021-11-25T17:44:33ZThe Role of CDK4 in the Pathogenesis of Pancreatic Cancer10.3390/healthcare91114782227-9032https://doaj.org/article/89a39525326943deba1f1cb57e8fdadd2021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9032/9/11/1478https://doaj.org/toc/2227-9032Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches.Emily JiggensMaria MortoglouGuy H. GrantPinar Uysal-OnganerMDPI AGarticlepancreatic cancerCDK4CDK4/6 inhibitorepidemiologyMedicineRENHealthcare, Vol 9, Iss 1478, p 1478 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pancreatic cancer CDK4 CDK4/6 inhibitor epidemiology Medicine R
spellingShingle	pancreatic cancer CDK4 CDK4/6 inhibitor epidemiology Medicine R Emily Jiggens Maria Mortoglou Guy H. Grant Pinar Uysal-Onganer The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
description	Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches.
format	article
author	Emily Jiggens Maria Mortoglou Guy H. Grant Pinar Uysal-Onganer
author_facet	Emily Jiggens Maria Mortoglou Guy H. Grant Pinar Uysal-Onganer
author_sort	Emily Jiggens
title	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_short	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_full	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_fullStr	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_full_unstemmed	The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
title_sort	role of cdk4 in the pathogenesis of pancreatic cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/89a39525326943deba1f1cb57e8fdadd
work_keys_str_mv	AT emilyjiggens theroleofcdk4inthepathogenesisofpancreaticcancer AT mariamortoglou theroleofcdk4inthepathogenesisofpancreaticcancer AT guyhgrant theroleofcdk4inthepathogenesisofpancreaticcancer AT pinaruysalonganer theroleofcdk4inthepathogenesisofpancreaticcancer AT emilyjiggens roleofcdk4inthepathogenesisofpancreaticcancer AT mariamortoglou roleofcdk4inthepathogenesisofpancreaticcancer AT guyhgrant roleofcdk4inthepathogenesisofpancreaticcancer AT pinaruysalonganer roleofcdk4inthepathogenesisofpancreaticcancer
_version_	1718412054660907008

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

Ejemplares similares